LONDON— AstraZeneca AZN 1.33% PLC told European Union officials that fewer doses of its Covid-19 vaccine will be ready for the bloc’s planned rollout in early February, blaming an unspecified manufacturing issue.
The shortfall comes as European leaders face heightened scrutiny over what critics say has been a slower rollout of several Western-developed vaccines than in the U.S. and U.K. It also comes after European officials clashed this week with Pfizer Inc. and BioNTech SE over the companies’ decision to cut their own planned deliveries of Covid-19 vaccines to the bloc.
The dual shortfalls put the Continent’s plans to accelerate its vaccine drive at risk. EU nations have placed big orders for the AstraZeneca shot, partly because it doesn’t require the cold storage needed for the Pfizer-BioNTech vaccine. Officials have been banking on the arrival of their AstraZeneca orders next month to speed up bloc-wide vaccinations.
The AstraZeneca disclosure also threatens a fresh reputational hit to the British pharmaceutical giant, which partnered with the University of Oxford in developing the vaccine. AstraZeneca is responsible for manufacturing and distribution of the vaccine, as well as regulatory approvals.
The company has previously faced criticism over how it initially communicated results of the vaccine’s late-stage human trials.
Europe’s commissioner for health and food safety, Stella Kyriakides, said on Twitter Friday night that EU member states expressed deep dissatisfaction with AstraZeneca’s vaccine-delivery delays. The European Commission will press AstraZeneca on precise delivery volumes and schedules so that countries can plan vaccinations, she said.
Austria’s health-care minister Rudolf Anschober said that AstraZeneca’s move was unacceptable. The company’s commitments to delivery must be honored, Mr. Anschober said Friday. A spokesman for the European Commission said that AstraZeneca confirmed a “change of its delivery schedule” and that the commission was working to find out more details.
AstraZeneca said it would still be able to start delivering vaccines upon anticipated approval of the shot in Europe, a spokesman said Friday evening. The European Medicines Agency is scheduled to review the AstraZeneca vaccine next week. If approved, the vaccine could start rolling out in early February.